Tandem mass tag­based quantitative proteomic profiling identifies novel serum biomarkers of drug­induced liver injury in humans

Tandem mass tag-based quantitative proteomic profiling identifies novel serum biomarkers of drug-induced liver injury in humans. Nature Communications, 14. 1215 1-14. ISSN 2041-1723

[1]  W. Tong,et al.  Assessment of the Frequency, Phenotypes, and Outcomes of Acute Liver Injury Associated with Amoxicillin/Clavulanate in 1.4 Million Patients in the Veterans Health Administration , 2022, Drug Safety.

[2]  C. Stephens,et al.  A new framework for advancing in drug-induced liver injury research. The Prospective European DILI Registry , 2022, Liver international : official journal of the International Association for the Study of the Liver.

[3]  N. Henderson,et al.  Liver zonation, revisited , 2022, Hepatology.

[4]  Mitchell R. McGill,et al.  Redrawing the map to novel DILI biomarkers in circulation: Where are we, where should we go, and how can we get there? , 2021, Livers.

[5]  A. Gerbes,et al.  Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review , 2021, Expert opinion on drug metabolism & toxicology.

[6]  E. Björnsson.  Clinical management of patients with drug‐induced liver injury (DILI) , 2021, United European gastroenterology journal.

[7]  J. Dear,et al.  Evaluating the Sensitivity and Specificity of Promising Circulating Biomarkers to Diagnose Liver Injury in Humans. , 2021, Toxicological sciences : an official journal of the Society of Toxicology.

[8]  S. Kaneko,et al.  LECT2 as a hepatokine links liver steatosis to inflammation via activating tissue macrophages in NASH , 2021, Scientific reports.

[9]  Ming Niu,et al.  Metabolomics Profiling and Diagnosis Biomarkers Searching for Drug-Induced Liver Injury Implicated to Polygonum multiflorum: A Cross-Sectional Cohort Study , 2020, Frontiers in Medicine.

[10]  J. Long,et al.  Molecular Biomarkers in Drug-Induced Liver Injury: Challenges and Future Perspectives , 2020, Frontiers in Pharmacology.

[11]  Mitchell R. McGill,et al.  Identification of Serum Biomarkers to Distinguish Hazardous and Benign Aminotransferase Elevations. , 2019, Toxicological sciences : an official journal of the Society of Toxicology.

[12]  Anthony C Breu,et al.  A Multicenter Study Into Causes of Severe Acute Liver Injury , 2019, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[13]  Michelle A. Anderson,et al.  Constitutive release of CPS1 in bile and its role as a protective cytokine during acute liver injury , 2019, Proceedings of the National Academy of Sciences.

[14]  Gary D Bader,et al.  Single cell RNA sequencing of human liver reveals distinct intrahepatic macrophage populations , 2018, Nature Communications.

[15]  Jiri Aubrecht,et al.  Candidate biomarkers for the diagnosis and prognosis of drug‐induced liver injury: An international collaborative effort , 2018, Hepatology.

[16]  H. Barnhart,et al.  Death and liver transplantation within 2 years of onset of drug‐induced liver injury , 2017, Hepatology.

[17]  Y. Li,et al.  Glutathione S-transferase A1 (GSTA1) as a marker of acetaminophen-induced hepatocyte injury in vitro , 2017, Toxicology mechanisms and methods.

[18]  Michael Merz,et al.  Drug-induced liver injury: recent advances in diagnosis and risk assessment , 2017, Gut.

[19]  Lanjuan Li,et al.  Proteomic Signature of Acute Liver Failure: From Discovery and Verification in a Pig Model to Confirmation in Humans* , 2017, Molecular & Cellular Proteomics.

[20]  A. Vickers,et al.  Liver Effects of Clinical Drugs Differentiated in Human Liver Slices , 2017, International journal of molecular sciences.

[21]  J. Aronson,et al.  Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature , 2016, BMC Medicine.

[22]  K. Chiba,et al.  Characterization of release profile of ornithine carbamoyltransferase from primary rat hepatocytes treated with hepatotoxic drugs: Implications for its unique potential as a drug-induced liver injury biomarker. , 2016, Drug metabolism and pharmacokinetics.

[23]  William M. Lee,et al.  Persistent Liver Biochemistry Abnormalities Are More Common in Older Patients and those With Cholestatic Drug Induced Liver Injury , 2015, The American Journal of Gastroenterology.

[24]  Bruno Domon,et al.  Large-Scale Targeted Proteomics Using Internal Standard Triggered-Parallel Reaction Monitoring (IS-PRM)* , 2015, Molecular & Cellular Proteomics.

[25]  G. von Heijne,et al.  Tissue-based map of the human proteome , 2015, Science.

[26]  Matthew E. Ritchie,et al.  limma powers differential expression analyses for RNA-sequencing and microarray studies , 2015, Nucleic acids research.

[27]  Jingli Liu,et al.  Glutathione S-transferase A1 (GSTA1) release, an early indicator of acute hepatic injury in mice. , 2014, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association.

[28]  R. Fontana,et al.  Carbamoyl phosphate synthetase-1 is a rapid turnover biomarker in mouse and human acute liver injury. , 2014, American journal of physiology. Gastrointestinal and liver physiology.

[29]  C. Stephens,et al.  Use of Hy's law and a new composite algorithm to predict acute liver failure in patients with drug-induced liver injury. , 2014, Gastroenterology.

[30]  Mitchell R. McGill,et al.  Argininosuccinate synthetase as a plasma biomarker of liver injury after acetaminophen overdose in rodents and humans , 2014, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[31]  L. Hood,et al.  Quantitative Liver-Specific Protein Fingerprint in Blood: A Signature for Hepatotoxicity , 2014, Theranostics.

[32]  K. Flanigan,et al.  Pharmacokinetics and safety of single doses of drisapersen in non-ambulant subjects with Duchenne muscular dystrophy: Results of a double-blind randomized clinical trial , 2013, Neuromuscular Disorders.

[33]  A. Elsharkawy,et al.  Clinical and laboratory features and natural history of seronegative hepatitis in a nontransplant centre , 2013, European journal of gastroenterology & hepatology.

[34]  Frank D Sistare,et al.  A performance evaluation of three drug-induced liver injury biomarkers in the rat: alpha-glutathione S-transferase, arginase 1, and 4-hydroxyphenyl-pyruvate dioxygenase. , 2012, Toxicological sciences : an official journal of the Society of Toxicology.

[35]  J. Senior,et al.  Alanine Aminotransferase: A Clinical and Regulatory Tool for Detecting Liver Injury–Past, Present, and Future , 2012, Clinical pharmacology and therapeutics.

[36]  K. Ghoshal,et al.  Stat3‐mediated activation of microRNA‐23a suppresses gluconeogenesis in hepatocellular carcinoma by down‐regulating Glucose‐6‐phosphatase and peroxisome proliferator‐activated receptor gamma, coactivator 1 alpha , 2012, Hepatology.

[37]  R. Fontana,et al.  Serum proteomic profiling in patients with drug‐induced liver injury , 2012, Alimentary pharmacology & therapeutics.

[38]  M. Tomita,et al.  Serum metabolomics reveals γ-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. , 2011, Journal of hepatology.

[39]  Hannes Planatscher,et al.  A generic operational strategy to qualify translational safety biomarkers. , 2011, Drug discovery today.

[40]  M. Molokhia,et al.  Case Definition and Phenotype Standardization in Drug‐Induced Liver Injury , 2011, Clinical pharmacology and therapeutics.

[41]  Edward L. Huttlin,et al.  A Tissue-Specific Atlas of Mouse Protein Phosphorylation and Expression , 2010, Cell.

[42]  P. Ganey,et al.  Idiosyncratic drug-induced liver injury and the role of inflammatory stress with an emphasis on an animal model of trovafloxacin hepatotoxicity. , 2010, Toxicological sciences : an official journal of the Society of Toxicology.

[43]  Brendan MacLean,et al.  Bioinformatics Applications Note Gene Expression Skyline: an Open Source Document Editor for Creating and Analyzing Targeted Proteomics Experiments , 2022 .

[44]  A. Nagata,et al.  Superiority of serum type-I arginase and ornithine carbamyltransferase in the detection of toxicant-induced acute hepatic injury in rats. , 2008, Clinica chimica acta; international journal of clinical chemistry.

[45]  U. Malmqvist,et al.  Muscular exercise can cause highly pathological liver function tests in healthy men. , 2008, British journal of clinical pharmacology.

[46]  Steven P Gygi,et al.  Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry , 2007, Nature Methods.

[47]  James H. Lewis,et al.  ‘Hy's law,’ the ‘Rezulin Rule,’ and other predictors of severe drug‐induced hepatotoxicity: putting risk‐benefit into perspective , 2006, Pharmacoepidemiology and drug safety.

[48]  R. Hayes,et al.  Identification and preliminary validation of novel biomarkers of acute hepatic ischaemia/reperfusion injury using dual-platform proteomic/degradomic approaches , 2006, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[49]  S. Kaneko,et al.  Detection of autoantibody to aldolase B in sera from patients with troglitazone-induced liver dysfunction. , 2005, Toxicology.

[50]  K. Hatakeyama,et al.  Serum LECT2 level as a prognostic indicator in acute liver failure. , 2004, Transplantation proceedings.

[51]  M. Kaplan,et al.  Evaluation of abnormal liver-enzyme results in asymptomatic patients. , 2000, The New England journal of medicine.

[52]  J. Yates,et al.  An approach to correlate tandem mass spectral data of peptides with amino acid sequences in a protein database , 1994, Journal of the American Society for Mass Spectrometry.

[53]  G. Danan,et al.  Causality assessment of adverse reactions to drugs--I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. , 1993, Journal of clinical epidemiology.

[54]  A. Tegeris,et al.  Ornithine carbamyl transferase as a liver function test comparative studies in the dog, swine, and man. , 1969, Toxicology and applied pharmacology.